在Leishmania主要诱导的皮肤Leishmaniasis中制备和表征带有甲基甲的体
Uranous Niroumand1,2, Mohammad Hossein Motazedian3, Fatemeh Ahmadi4
1Department of Pharmaceutical Nanotechnology, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz-Marvdasht Hwy, Karafarin St, Shiraz, 71468 64685, Fars, Iran.
Scientific reports
|May 2, 2024
概括
新型甲基 (ART) 载荷的基体显示出对大莱什曼亚病毒的增强抗莱什曼亚病毒活性. 这些局部尼索姆可提高皮肤莱什曼病治疗的疗效,降低皮肤莱什曼病治疗的毒性.
科学领域:
- 制药科学 制药科学
- 寄生虫学的寄生虫学
- 皮肤病学 皮肤病学
背景情况:
- 皮肤莱什曼病是一种广泛的寄生虫性皮肤感染.
- 现有的治疗方法面临着有效性和不良影响的挑战.
- 新型局部药物输送系统对于有效管理至关重要.
研究的目的:
- 为了配制甲基 (ART) 载荷的体,用于局部输送.
- 为了评估ART载荷的体对大莱什曼病的抗莱什曼病疗效,针对大莱什曼病.
- 评估开发的阴性体配方的体外和体内性能.
主要方法:
- 通过薄膜水化技术制备的ART载荷的体.
- 特性包括粒子大小,泽塔潜力,形态学,DSC,药物加载和释放研究.
- 在实验室中进行了细胞毒性和抗莱什曼活性测试.
- 在动物模型中评估了体内疗效.
主要成果:
- 球形ART加载的体 (100-300nm) 实现了>99%的封装效率.
- 与免费ART相比,尼奥索姆在体外表现出更高的抗莱什曼病毒活性和选择性指数.
- IC50值:ART (39.09 微克/毫升),ART-尼奥索姆 (15.12 微克/毫升),脂质体安福特里辛B (20 微克/毫升).
- 在体内研究证实了300nmART-niosomes显著的抗莱什曼效应.
结论:
- 装有ART的体体是一种有前途的局部药物递送系统.
- 该配方增强了抗莱什曼病毒的疗效,并降低了毒性.
- 尼奥索姆提供了一种可行的策略,用于管理皮肤莱什曼病.
相关概念视频
01:30Leishmaniasis
Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
01:21Antiprotozoal Agents
Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...